SureTrader
Nadex Advertisement
Interactive Brokers Advertisement
Home > Boards > US OTC > Biotechs >

Galectin Therapeutics Inc. (GALT)

GALT RSS Feed
Add GALT Price Alert      Hide Sticky   Hide Intro
Moderator: Chess Master, GREGG THE GREEK
Search This Board: 
Last Post: 7/24/2017 12:14:32 PM - Followers: 75 - Board type: Free - Posts Today: 1

Galectin Therapeutics is a biotechnology company focused on discovery and development. We apply our leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on our unique carbohydrate technology target galectin proteins, which are key mediators of biologic and pathologic function.

Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life-threatening consequences to patients, and those where current treatment options are limited. Our strategy is to establish clinical development approaches that add value to the Company in the shortest time possible, and to seek partners as the program advances and requires much greater resources.

Galectin Therapeutics leverages extensive scientific and development expertise as well as established relationships with outside sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer immunotherapy.
 

Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life-threatening consequences to patients, and those where current treatment options are limited. Though we do not have any current marketed products, our research and development programs, designed to ultimately help patients and their physicians, are focused on:

 

Fibrosis

 

Fibrosis is the development of excess fibrous connective tissue in an organ when exposed to a chronic disease. The longer the disease affects the organ, the more fibrous tissue is deposited and this ultimately results in the failure of the organ. Galectin Therapeutics’ drug candidates provide a promising and exciting new approach for the treatment of fibrotic diseases, including liver, lung and kidney fibrosis. Significant unmet need exists for treatment options in fibrosis. For example, there are currently no approved medical treatments available for the millions of patients in the U.S. who have non-alcoholic steatohepatitis with advanced fibrosis – commonly known as fatty liver disease. Learn about fibrosis and our research in this area including galectin effects on liver fibrosis, lung fibrosis and kidney fibrosis.

 

Cancer

 

Cancer harms the body when damaged cells divide uncontrollably to form lumps or masses of tissue called tumors. Research shows the potential for galectin inhibition to play an important role in cancer therapy, particularly tumor immunotherapy – an emerging treatment that enhances the activity of the immune system against cancer cells. There are more than 100 types of cancers, and for many of these cancers, few treatment options exist. Our drug candidates provide a new and complimentary approach to other drugs on the market for the treatment of cancer. Learn more about cancer and immunotherapy.

 

GALT
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
GALT News: Galectin Therapeutics to Present at the Singular Research Summer Conference 07/07/2017 12:00:00 PM
GALT News: Ammo, Inc. Appoints Two Senior Executives to Board of Directors 06/29/2017 09:02:00 AM
GALT News: Patent for Reducing Inflammatory Response Granted to Galectin Therapeutics 06/21/2017 08:30:00 AM
GALT News: Galectin Therapeutics Announces Important Milestones towards Completion of NASH CX Trial 06/13/2017 08:30:00 AM
GALT News: Generic Drugs Stocks on Investors' Radar -- Catalyst Pharma, Lannett, Evoke Pharma, and Galectin Therapeutics 06/07/2017 07:05:00 AM
PostSubject
#3164   The July 13 presentation is now in the jmh0602 07/24/17 12:14:32 PM
#3163   In the PR they said recording will be Amatuer17 07/18/17 02:57:30 PM
#3162   No, not sure there is one. I thought gss2003 07/18/17 12:53:05 PM
#3161   Has anyone found the recorded webcast for the conf? Amatuer17 07/17/17 08:45:43 PM
#3160   Thanks for the article Interesting to see mention of Amatuer17 07/10/17 09:08:30 PM
#3159   article on NASH - Jim is part of jmh0602 07/10/17 02:12:46 PM
#3158   Yes they are very different trials but the Amatuer17 06/25/17 10:29:21 AM
#3157   FX and CX two very different trials. biotechexpert 06/24/17 02:26:21 AM
#3156   The failed FX trial is creating doubt in Amatuer17 06/23/17 06:14:56 AM
#3155   "This trial was designed and is being conducted jmh0602 06/22/17 08:38:16 PM
#3154   Agreed 100% no side effects and low drop Chess Master 06/19/17 08:55:30 PM
#3153   I checked the clinical study site. IRAHopeful 06/19/17 01:37:13 PM
#3152   I don't know what the symptoms are for IRAHopeful 06/19/17 12:07:58 PM
#3151   Extremely low drop out rate. Patients must biotechexpert 06/14/17 09:22:07 PM
#3150   Not a bad strategy. How much are $5 gss2003 06/14/17 12:36:44 PM
#3149   As per today's PR - yes Now the question Amatuer17 06/14/17 12:20:55 PM
#3148   We've been hearing how safe the drug is jmh0602 06/14/17 12:11:34 PM
#3147   DSMB meeting - good results on safety 68% patients Amatuer17 06/14/17 08:03:11 AM
#3146   Maybe for leverage purposes, but the need one gss2003 06/12/17 08:29:53 PM
#3145   But they act like they don't want/need a Coolec78 06/12/17 07:49:40 PM
#3144   Maybe not for the trial, but definitely for gss2003 06/10/17 10:26:45 AM
#3143   No matter what - they will need a Amatuer17 06/10/17 06:04:33 AM
#3142   With current management yes they are going to Chess Master 06/09/17 08:44:24 PM
#3141   I would imagine they will get a partner gss2003 06/09/17 04:19:56 PM
#3140   IF that happens... GREGG THE GREEK 06/09/17 04:17:15 PM
#3139   Thanks for Clarifying CM. It's all good to RyGuy 06/09/17 04:05:54 PM
#3138   If that happens - assume there will be Amatuer17 06/09/17 03:08:17 PM
#3137   I just wanted to clarify what you said. Chess Master 06/09/17 02:43:34 PM
#3136   Looks good seeing GALT back on the rise. RyGuy 06/08/17 03:39:42 PM
#3135   GALT is one of the 3 companies in Amatuer17 06/01/17 07:51:25 PM
#3134   Right now GALT is in the drivers seat RyGuy 05/27/17 09:24:50 PM
#3133   I picked up more Monday and am pleasantly rickyricks 05/27/17 06:16:30 PM
#3132   I think your analysis is spot on but Chess Master 05/26/17 08:07:08 PM
#3131   Not getting to $10 without either a major gss2003 05/26/17 06:32:34 PM
#3130   Article on GALT... RyGuy 05/26/17 03:45:03 PM
#3129   GALT moving back up nicely today RyGuy 05/26/17 02:39:53 PM
#3128   Been watching some 1.16s sail away Bearly Bullish 05/26/17 02:36:10 PM
#3127   Oversold from scared traders. Now GALT begins progressing RyGuy 05/26/17 01:37:53 PM
#3126   Yup, he went all in !!!!!! Coolec78 05/25/17 12:45:27 PM
#3125   did you see them yet? got a link Chess Master 05/24/17 11:07:26 PM
#3124   INSIDER Buying! I know its small but Chess Master 05/24/17 11:05:56 PM
#3123   GALT buy 2.3201 stocktrademan 05/24/17 12:09:50 PM
#3122   Galecto results are 2 days old, not sure gss2003 05/24/17 05:59:09 AM
#3120   Thank you for challenging him. Biotech is Chess Master 05/23/17 10:37:01 PM
#3119   Not so fast. You need to cut Chess Master 05/23/17 10:28:11 PM
#3118   I love how you say "they have 15 RyGuy 05/23/17 07:47:17 PM
#3117   According to the GALT filing, they have over biotech2010 05/23/17 06:59:21 PM
#3116   Galecto’s Inhaled TD139 Effective, Safe in Treating IPF FLGuy2017 05/23/17 04:49:49 AM
#3115   It was an over reaction but way less Chess Master 05/23/17 12:37:13 AM
#3114   This will head back up, as people realize RyGuy 05/22/17 05:34:55 PM
PostSubject